|
COBRA1 expression based on
|
Statistics: Unpaired two sample T-test was employed to evaluate levels of significance in expression level between any two sample groups
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.526200E-02 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
9.097800E-02 |
| Normal-vs-Stage2 |
2.976200E-01 |
| Normal-vs-Stage3 |
1.322170E-01 |
| Normal-vs-Stage4 |
5.002400E-01 |
| Stage1-vs-Stage2 |
9.291800E-01 |
| Stage1-vs-Stage3 |
8.596600E-01 |
| Stage1-vs-Stage4 |
6.661200E-01 |
| Stage2-vs-Stage3 |
9.824800E-01 |
| Stage2-vs-Stage4 |
7.223400E-01 |
| Stage3-vs-Stage4 |
6.353000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.617900E-02 |
| Normal-vs-AfricanAmerican |
5.301600E-02 |
| Normal-vs-Asian |
1.454410E-01 |
| Caucasian-vs-AfricanAmerican |
1.978760E-01 |
| Caucasian-vs-Asian |
9.354200E-01 |
| AfricanAmerican-vs-Asian |
2.852800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.990300E-02 |
| Normal-vs-Female |
1.273170E-01 |
| Male-vs-Female |
4.555400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.854400E-02 |
| Normal-vs-Age(41-60Yrs) |
7.074400E-02 |
| Normal-vs-Age(61-80Yrs) |
6.046800E-01 |
| Normal-vs-Age(81-100Yrs) |
7.041000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.334400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.835200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.918200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.994000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.323400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.561800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.035400E-01 |
| Classical-VS-Follicular |
9.084300E-03 |
| Classical-VS-Other |
5.394600E-01 |
| Classical-VS-Normal |
7.280400E-03 |
| Tall-VS-Follicular |
3.861200E-01 |
| Tall-VS-Other |
9.763000E-01 |
| Tall-VS-Normal |
6.529200E-01 |
| Follicular-VS-Other |
7.142400E-01 |
| Follicular-VS-Normal |
5.824000E-01 |
| Other-VS-Normal |
8.560800E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.307500E-02 |
| Normal-vs-N1 |
5.689400E-01 |
| N0-vs-N1 |
3.430100E-02 |
|
|
